Flag­ship launch­es first UK-based start­up to un­cov­er genes that make cells vul­ner­a­ble or re­sis­tant to dis­ease

A new biotech start­up be­lieves that ge­net­ic di­ver­si­ty found among the tril­lions of cells that com­prise an in­di­vid­ual per­son could hold the keys to new clues for treat­ing or pre­vent­ing dis­ease.

Flag­ship Pi­o­neer­ing, a life sci­ences in­vest­ment firm that builds its own biotech star­tups, an­nounced an ini­tial $50 mil­lion com­mit­ment to Quo­tient Ther­a­peu­tics at its launch from stealth on Tues­day morn­ing.

In a first for Flag­ship, which usu­al­ly keeps its com­pa­nies close to its home base around Boston, Quo­tient launched with the ma­jor­i­ty of its em­ploy­ees in Cam­bridge, UK. A spokesper­son for Flag­ship said the life sci­ences firm’s UK of­fices will of­fi­cial­ly open next week.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER